| Literature DB >> 35208994 |
Dmitriy Berillo1,2, Marzhan Kozhahmetova1,2, Lina Lebedeva3.
Abstract
Rumex confertus belongs to the genus Rumex and is classified as an invasive parasitic plant in agriculture. Despite other Rumex species being widely used in herbal medicine due to their antimicrobial, antioxidant, antitumor, and anti-inflammatory effects, there are almost no information about the potential of Rumex confertus for the treatment of various diseases. In this review we analyzed scientific articles revealing properties of Rumex plant's substances against cancer, diabetes, pathogenic bacterial invasions, viruses, inflammation, and oxidative stress for the past 20 years. Compounds dominating in each composition of solvents for extraction were discussed, and common thin layer chromatography(TLC) and high performance liquid chromatography(HPLC) methods for efficient separation of the plant's extract are included. Physico-chemical properties such as solubility, hydrophobicity (Log P), pKa of flavonoids, anthraquinones, and other derivatives are very important for modeling of pharmacokinetic and pharmacodynamics. An overview of clinical studies for abounded selected substances of Rumex species is presented.Entities:
Keywords: Rumex confertus; anthraquinone derivatives; emodin; epigallocatechin; epigallocatechin gallate; flavonoids; herbal medicine
Mesh:
Substances:
Year: 2022 PMID: 35208994 PMCID: PMC8880800 DOI: 10.3390/molecules27041204
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chromatogram (RP-HPLC) of methanolic extracts from the leaves of R. confertus reproduced with the permission of Smolarz [8].
Physico-chemical and toxicity data of extractive substances.
|
|
|
| |
| Emodin | Aloe-emodin | Rhein | |
|
|
|
| |
| Leucocyanidin | Chrysophanol or chrysophanic acid (1,8-dihydroxy-3-methylanthracene-9,10-dione) | Physcion (1,8-Dihydroxy-6-methoxy-3-methylanthraquinone) or emodin monomethyl ether | |
|
|
| ||
| Epigallocatechin gallate (EGCG) | Epigallocatechin (EGC) | ||
|
|
| ||
| Barbaloin or Aloin A | Sennoside (-)-(9R*,9′R*)-5,5′-bis(β-D-gluco-pyranosyloxy)-4,4′-dihydroxy-10,10′-dioxo-9,9′,10,10′-tetrahydro-9,9′-bianthracene-2,2′-dicarboxylic acid | ||
Figure 2Influence of different concentrations of ethanol extract and emodin of leaves of R. confertus on the viability of EAC cells in vitro, adapted from Antonyan et al. [35].
Figure 3Correlation between emodin and ethanol extract of leaves of Rumex Confertus on the viability hippocampal cells, adapted from Antonyan et al. [35].
Clinical trials of plant’s extractive substances.
| Compound | Effect | Action | Clinical Experiment |
|---|---|---|---|
| Epigallocatechin gallate [ | neuroprotective and neurorescue effects | modulation of cell survival and cell cycle genes | A randomised, double-blind, placebo-controlled, balanced crossover study the effects of 135 mg and 270 mg pure EGCG in 24 healthy, young adults (18–35) |
| Emodin [ | antiproliferative effect | inhibits the activity of the 26S proteasome in vitro and in vivo | HEK293A-luciferase-cODC cells were seeded in 96-well plates and treated in the presence of emodin |
| Sennoside [ | laxative | increasing cyclic 3′,5′-adenosine monophosphate it alter permeability of cell walls in the colon, which regulates the process of active ion secretion | Participants aged 10–18 years were randomly assigned to receive either PEG 60 mL/kg/day or PEG 30 mL/kg/day plus oral bisacodyl 10–15 mg/day or sennosides 2 mg/kg/day for 2 days prior to the colonoscopy |
| Aloe-emodin [ | Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease | MRI calculated kidney volume, eGFR [Time Frame: Every 3–6 months] | Interventional 300 participants from 15 to 70 years (child, adult, older adult) Randomized administration of Emodin (Frangula emodin, Frangulic acid) at concentration 100 mg/d |
| Epigallocatechin anticancer drug [ | To determine whether the daily consumption of decaffeinated green tea catechins (Polyphenon E®) for 1 year reduces the rate of progression to prostate cancer (PCa) in men diagnosed with HGPIN or ASAP | Study of Polyphenon E in Men with High-grade Prostatic Intraepithelial Neoplasia | 240 (120 men/arm) men 30 Years to 80 Years (adult, older adult) diagnosed with the prostate condition HGPIN or ASAP with a capsule form of standardized green tea extract called Polyphenon E (200 mg epigallocatechin gallate (EGCG) twice a day) or placebo for a 12-month period and see if it can prevent progression of the prostate condition to prostate cancer. Investigators wanted to see if Polyphenon E reduces lower urinary tract symptoms and if this can be taken safely over one year |